title: Phase II study of vindesine, cisplatin, and hexamethylmelamine (VCH) in small cell carcinoma of the lung.
abstract: Forty-two patients with small cell carcinoma of the lung were treated with cycles given every 28 days consisting of a combination of vindesine (3 mg/m2 if on Days 1 and 15), cisplatin (75 mg/m2 iv on Day 1), and hexamethylmelamine (200 mg/m2 orally on Days 8-22). Thirty-four patients were evaluable for response. Partial remission (PR) or complete remission (CR) was noted in seven (three CRs and four PRs) of nine previously untreated patients (77%) and in eight (one CR and seven PRs) of 25 patients treated previously with intensive chemotherapy (32%). This drug combination deserves consideration for inclusion in sequential combination chemotherapy regimens.
mesh_terms: D000328:Adult; D000368:Aged; D006585:Altretamine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000139:chemically induced; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014751:Vindesine
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D006585:Altretamine; D014751:Vindesine